← Back to Clinical Trials
Recruiting NCT07573124

NCT07573124 Efficacy of Combining Mulligan Spinal Mobilization With Leg Movement and Mechanical Lumbar Traction in Lumbar Radiculopathy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07573124
Status Recruiting
Phase —
Sponsor Khyber Medical University Peshawar
Condition Lumbar Radiculopathy
Study Type INTERVENTIONAL
Enrollment 32 participants
Start Date 2026-04-01
Primary Completion 2026-10-15

Eligibility & Interventions

Sex All sexes
Min Age 20 Years
Max Age 50 Years
Study Type INTERVENTIONAL
Interventions
Spinal Mobilization with Leg Movement (SMWLM)Mechanical Lumbar TractionConventional Physical Therapy

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 32 participants in total. It began in 2026-04-01 with a primary completion date of 2026-10-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Lumbar radiculopathy (LR), often caused by disc herniation, results in significant pain, disability, and reduced quality of life. Spinal Mobilization with Leg Movement (SMWLM) is a manual technique that has shown promise, while mechanical lumbar traction is used to reduce nerve compression, though its standalone effectiveness is debated. This randomized controlled trial aims to compare the combined effect of SMWLM plus mechanical lumbar traction against SMWLM alone, both administered with conventional physiotherapy. Outcomes will be assessed over 4 weeks to determine if the combined intervention offers superior pain relief, functional improvement, and range of motion in patients with unilateral L4-L5 or L5-S1 radiculopathy.

Eligibility Criteria

Inclusion Criteria: * Age 20-50 years * Male and female participants * Unilateral radiculopathy due to L4-L5 or L5-S1 disc bulge, confirmed by clinical examination and MRI * Symptom duration of 4 weeks to 6 months * Positive Straight Leg Raise (SLR) test on the affected leg (\<70° of hip flexion) * Pain intensity \<7 on the Numeric Pain Rating Scale (NPRS; mild to moderate pain) Exclusion Criteria: * Cognitive impairment, dementia, central cord signs * Inflammatory or degenerative spine conditions * Spine surgery within the last 6 months * Pregnant women in the later half of 2nd trimester or 3rd trimester * Muscular involvement (e.g., Deep Gluteal syndrome, Piriformis syndrome) * Currently receiving medications or other contemporaneous treatment

Contact & Investigator

Central Contact

Muhammad Haris, DPT

✉ drm.harispt@gmail.com

📞 +92 349 5959672

Principal Investigator

Muhammad Haris, DPT

PRINCIPAL INVESTIGATOR

Institute of Health Science, Khyber Medical University Islamabad

Frequently Asked Questions

Who can join the NCT07573124 clinical trial?

This trial is open to participants of all sexes, aged 20 Years or older, up to 50 Years, studying Lumbar Radiculopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07573124 currently recruiting?

Yes, NCT07573124 is actively recruiting participants. Contact the research team at drm.harispt@gmail.com for enrollment information.

Where is the NCT07573124 trial being conducted?

This trial is being conducted at Islamabad, Pakistan.

Who is sponsoring the NCT07573124 clinical trial?

NCT07573124 is sponsored by Khyber Medical University Peshawar. The principal investigator is Muhammad Haris, DPT at Institute of Health Science, Khyber Medical University Islamabad. The trial plans to enroll 32 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology